Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | JAK3 |
Variant | E183G |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | JAK3 E183G lies within the FERM domain of the Jak3 protein (UniProt.org). E183G confers a gain of function to the Jak3 protein as demonstrated by increased protein stability compared to wild-type, increased Stat5a phosphorylation, and transformation in cultured cells (PMID: 21821710). |
Associated Drug Resistance | |
Category Variants Paths |
JAK3 mutant JAK3 act mut JAK3 E183G |
Transcript | NM_000215.4 |
gDNA | chr19:g.17843045T>C |
cDNA | c.548A>G |
Protein | p.E183G |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047438786.1 | chr19:g.17843045T>C | c.548A>G | p.E183G | RefSeq | GRCh38/hg38 |
NM_000215 | chr19:g.17843045T>C | c.548A>G | p.E183G | RefSeq | GRCh38/hg38 |
NM_000215.3 | chr19:g.17843045T>C | c.548A>G | p.E183G | RefSeq | GRCh38/hg38 |
NM_000215.4 | chr19:g.17843045T>C | c.548A>G | p.E183G | RefSeq | GRCh38/hg38 |
XM_011527991.3 | chr19:g.17843045T>C | c.548A>G | p.E183G | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK3 E183G | Advanced Solid Tumor | sensitive | Tofacitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human cells expressing JAK3 E183G in culture demonstrated decreased cell survival, increased G1 arrest, elevated apoptotic activity, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710). | 21821710 |